Skip to search formSkip to main contentSkip to account menu

Pegaptanib Sodium

Known as: Pegaptanib Octasodium 
The sodium salt form of pegaptanib, a 28-mer RNA aptamer covalently linked to two branched 20-kD polyethylene glycol (PEG) chains, with anti… 
National Institutes of Health

Related topics

Related topics

5 relations
0.09 ML pegaptanib 3.33 MG/ML Prefilled Syringe [Macugen]NX1838

Narrower (2)

EYE 001Macugen

Broader (1)

pegaptanib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
[Japan phase 3 study of pegaptanib sodium in patients with diabetic macular edema].
PURPOSE To evaluate the efficacy and safety of intravitreal injections of pegaptanib sodium in subjects with diabetic macular… 
2013
2013
Comparison of subconjunctivally injected bevacizumab , ranibizumab , and pegaptanib for inhibition of corneal neovascularization in a rat model 窑
AIM: To compare the efficacies of subconjunctival bevacizumab, ranibizumab, and pegaptanib sodium injections for the inhibition… 
2011
2011
[Long-term efficacy and safety profile of pegaptanib sodium for age-related macular degeneration with choroidal neovascularization--evaluation of extended phase II clinical trial].
Long-term efficacy and safety profile of pegaptanib was evaluated for age-related macular degeneration (AMD) with choroidal… 
2010
2010
Retinale angiomatöse Proliferationen mit assoziierter Pigmentepithelabhebung
ZusammenfassungHintergrundIm natürlichen Verlauf und in der Häufigkeit von Komplikationen wie dem Einriss im Pigmentepithel (RIP… 
2010
2010
Ocular Hemodynamic Response to Intravitreal Pegaptanib in Eyes with Exudative Age-Related Macular Degeneration
Purpose: To assess ocular hemodynamic response to intravitreal pegaptanib in patients with age related macular degeneration (AMD… 
2010
2010
Monotherapie der exsudativen altersbedingten Makuladegeneration bei kardiovaskulären Risikopatienten
ZusammenfassungHintergrundMit der intravitrealen Applikation von Ranibizumab (Lucentis®) oder Pegaptanib (Macugen®) stehen… 
2007
2007
Pegaptanib sodium for the treatment of ocular vascular disease
Pegaptanib sodium is a selective RNA aptamer that inhibits the 165 isoform of vascular endothelial growth factor (VEGF), a key… 
2007
2007
Efficacy and safety of pegaptanib sodium for macular edema secondary to Central Retinal Vein Occlusion (CRVO)
Purpose: To assess the efficacy and safety of pegaptanib in the treatment of macular edema secondary to CRVO. Methods… 
2005
2005
[Treatment of neovascular age-related macular degeneration with intravitreal vascular endothelial growth factor inhibitor--secondary publication].
Subfoveal neovascularization is the most frequent cause of severe visual loss in patients with age-related macular degeneration… 
2004
2004
VEGF Inhibition Study in Ocular Neovascularization–1 (VISION–1): Safety Evaluation From the Pivotal MacugenTM (Pegaptanib Sodium) Clinical Trials
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)